Clinical trials
Placebo - Control clinical trials
Below are recruiting placebo - control clinical trials, each written for real people, not researchers. We’re tracking 3,949 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06152497Recruiting
Histamine and muscle growth after strength training
This study looks at how histamine affects muscle building after resistance exercise. It may help us understand why some people build muscle better than others after strength training.
Ghent, Oost-VlaanderenAges 18–45 - NCT07792876Recruiting
Testing ketone and carbohydrate supplements in trained cyclists
This study is testing how taking ketone and carbohydrate supplements affects performance in trained cyclists. It is looking for male amateur cyclists who train regularly and have a high fitness level.
Ribeirão Preto, São PauloAges 20–50 - NCT07788833Recruiting
Postbiotic supplement for weight and metabolic health
This study tests a postbiotic supplement for weight management and metabolic health in healthy adults. It may help improve body weight, metabolic markers, and quality of life.
Dallas, TexasAges 18–55 - NCT07792980Recruiting
Study of gut bacteria in colon cancer surgery
This study uses AI to analyze gut bacteria (microbiome) in people with colon cancer before and after surgery, to see how it relates to the effectiveness of a treatment called MPRO. It may help improve recovery and outcomes.
Seoul, SeoulAges 20–80 - NCT07417124RecruitingPhase 1
Study of SNS851 for people with high liver fat
This study tests a new medicine called SNS851 in healthy volunteers to see if it is safe and tolerable. It may help people with high liver fat, though it is not yet known if it works.
MelbourneAges 18–60 - NCT07243171RecruitingPhase 1/Phase 2
Oral Ecnoglutide for overweight or obesity
This trial tests an oral medication called Ecnoglutide to help people with overweight or obesity lose weight. It is for Chinese adults who are not diabetic and have a stable weight.
Beijing, Beijing MunicipalityAges 18–65 - NCT06736574RecruitingPhase 3
Study of omecamtiv mecarbil for chronic heart failure with very weak heart pump
This study tests an investigational medicine (omecamtiv mecarbil) for people with chronic heart failure and very low pumping strength. It looks at whether the drug can help prevent heart failure events or the need for stronger treatments.
Alexander City, AlabamaAges 18–85 - NCT07529457Recruiting
Probiotic treatment for constipation in adults
This study tests whether a probiotic product can help adults with constipation have more regular bowel movements. Probiotics are beneficial bacteria that may improve digestive health.
Suzhou, JiangsuAges 18–65 - NCT06680830RecruitingPhase 2
Testing NEU-411 for early Parkinson's with LRRK2 gene change
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
Sun City, ArizonaAges 40–80 - NCT05624450RecruitingPhase 3
Test drug tozorakimab for hospitalized viral lung infection needing oxygen
This Phase 3 study tests tozorakimab to see if it helps people hospitalized with a viral lung infection that is causing low oxygen levels. You might qualify if you still need supplemental oxygen when the study starts.
Birmingham, AlabamaAges 18 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT05714085RecruitingPhase 2/Phase 3
Vericiguat study for children with heart failure
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Los Angeles, CaliforniaAges 4 weeks–17 years - NCT07451769Recruiting
Testing a new drug target for migraine relief
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
Glostrup MunicipalityAges 18–65 - NCT07573176RecruitingPhase 3
Seltorexant for Depression in Adults and Older Adults
This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.
Bryant, ArkansasAges 18–74 - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT06819592RecruitingPhase 3
Preventing early lung infections after severe brain injury
This study tests whether giving an antibiotic (ceftriaxone) early after a severe brain injury can prevent lung infections caused by the breathing machine (ventilator). It is for adults in the ICU who recently started on a ventilator due to a brain emergency.
Canberra, Australian Capital TerritoryAges 18 years+ - NCT07246941RecruitingPhase 1
Safety of RG6496 in Huntington's disease
This is an early-phase study testing a new drug (RG6496) for people with Huntington's disease. The study will check the drug's safety and how the body processes it, and it requires two doses given about 6 months apart.
Ciudad Autonoma Bs AsAges 25–65 - NCT06555952Recruiting
Grape seed extract for blood pressure and heart health
This trial tests whether a grape seed extract can help lower blood pressure in people with mildly high blood pressure and slightly elevated blood sugar. It's designed for adults aged 40-60 who are not on blood pressure or diabetes medications.
Chicago, IllinoisAges 40–60 - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+ - NCT06909565RecruitingPhase 4
Inclisiran to prevent heart and leg events after artery procedure
This study tests whether a twice-yearly injection called inclisiran can prevent heart attacks, strokes, or leg complications in people who recently had a procedure to open a blocked artery. You may be eligible if you had a heart or leg artery procedure within the last two weeks.
Alexander City, AlabamaAges 18 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT06914609RecruitingPhase 3
Study of ION582 for people with Angelman syndrome
This trial tests a new medicine called ION582 for people with Angelman syndrome. It aims to see if it can help with symptoms and is given as a lumbar puncture (spinal tap). You may be able to join if you have a genetic diagnosis of Angelman syndrome and are between 2 and 50 years old.
Los Angeles, CaliforniaAges 2–50 - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new Placebo - Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo - control?
- Yes. Clin2 currently lists 3,949 recruiting placebo - control studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo - control trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo - control trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.